The Hollywood Reporter won 13 first-place prizes at the 18th annual National Arts & Entertainment Journalism Awards, ...

How Did He Build This Underground Mansion By Hand? Top Four videos Thank you very much for your valuable time to Watch, Like, ...

Toni Braxton's 'He Wasn't Man Enough' has new life as Lifetime movie ...

Emily in Paris is back, but this time Emily’s in Rome—and Venice. Not to worry though; Paris definitely still makes an ...

Nov 21 (Reuters) - Eli Lilly (LLY.N), opens new tab hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its ...

Eli Lilly is inking a $100 million-plus biobucks deal with Insilico Medicine in hopes of using artificial intelligence to discover new drugs. The Indianapolis Big Pharma will combine Insilico’s Pharma ...

Eli Lilly announced a partnership with chipmaker NVIDIA on Tuesday to build what it claims will be the “most powerful supercomputer owned and operated by a pharmaceutical company.” Lilly’s technology ...

Eli Lilly stock (NYSE: LLY) is up 10% this month, a rise driven by strong clinical trial progress. This includes the announcement of positive Phase 3 results in October 2025 for its oral GLP-1 drug, ...

While most of what the FDA laid out in a recent draft guidance on the assessment of overall survival in oncology clinical trials was expected, the document still raised one concern for Eli Lilly’s ...

News provided by Eli Lilly and Company Oct 17, 2025, 8:00 AM ET Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, ...

Now four years into a first-in-class FDA approval for certain HR-positive, HER2-negative early breast cancers, Eli Lilly’s Verzenio has proven it can extend patients’ lives in the indication. Verzenio ...

Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk early breast cancer Seven-year results from the ...